FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893086056> ?p ?o ?g. }

• W2893086056 endingPage "1508" @default.
• W2893086056 startingPage "1500" @default.
• W2893086056 abstract "Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because of hyperprogression and pseudoprogression. The aim of this study was to investigate the factors associated with tumor response and serious outcomes.We retrospectively collected the medical records of 51 patients with advanced NSCLC who received PD-1/PD-L1 inhibitors between January 2016 and February 2018.The mean patient age was 63.9 years, and 72.5% (37/51) were male. Most (92.2%, 47/51) had received previous systemic treatment. The overall response rate was 21.6% (11/51). The response rate was significantly lower in patients with pleural or pericardial metastasis than in patients without pleural or pericardial metastasis (4.3% vs. 35.7%; P = 0.007). Patients with pleural or pericardial metastasis had a significantly higher rate of adverse events of any grade (91.3% vs. 50.0%; P = 0.002) and grade 3-5 adverse events (52.2% vs. 25.0%; P = 0.046).Pleural or pericardial metastasis is a significant factor affecting the efficacy and rate of adverse events in advanced NSCLC patients treated with PD-1/PD-L1 inhibitors. Clinicians should pay attention to the use of immune checkpoint inhibitors in lung cancer patients with pleural or pericardial metastasis." @default.
• W2893086056 created "2018-10-05" @default.
• W2893086056 creator A5021370060 @default.
• W2893086056 creator A5024232083 @default.
• W2893086056 creator A5033524900 @default.
• W2893086056 creator A5038680772 @default.
• W2893086056 creator A5048445311 @default.
• W2893086056 creator A5051699142 @default.
• W2893086056 creator A5054678209 @default.
• W2893086056 creator A5082791341 @default.
• W2893086056 creator A5090545099 @default.
• W2893086056 date "2018-09-25" @default.
• W2893086056 modified "2023-10-14" @default.
• W2893086056 title "Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors" @default.
• W2893086056 cites W1982488143 @default.
• W2893086056 cites W2009461892 @default.
• W2893086056 cites W2038934354 @default.
• W2893086056 cites W2066671159 @default.
• W2893086056 cites W2092997044 @default.
• W2893086056 cites W2098533764 @default.
• W2893086056 cites W2104347254 @default.
• W2893086056 cites W2111959821 @default.
• W2893086056 cites W2156353875 @default.
• W2893086056 cites W2165206691 @default.
• W2893086056 cites W2197694832 @default.
• W2893086056 cites W2198093519 @default.
• W2893086056 cites W2265285917 @default.
• W2893086056 cites W2293531514 @default.
• W2893086056 cites W2340636398 @default.
• W2893086056 cites W2509796692 @default.
• W2893086056 cites W2549414845 @default.
• W2893086056 cites W2559382297 @default.
• W2893086056 cites W2560367415 @default.
• W2893086056 cites W2567564314 @default.
• W2893086056 cites W2572174216 @default.
• W2893086056 cites W2604909450 @default.
• W2893086056 cites W2625720596 @default.
• W2893086056 cites W2762777471 @default.
• W2893086056 cites W2767553670 @default.
• W2893086056 cites W2791535137 @default.
• W2893086056 cites W2821553560 @default.
• W2893086056 cites W2890555947 @default.
• W2893086056 doi "https://doi.org/10.1111/1759-7714.12877" @default.
• W2893086056 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6209802" @default.
• W2893086056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30253080" @default.
• W2893086056 hasPublicationYear "2018" @default.
• W2893086056 type Work @default.
• W2893086056 sameAs 2893086056 @default.
• W2893086056 citedByCount "17" @default.
• W2893086056 countsByYear W28930860562019 @default.
• W2893086056 countsByYear W28930860562020 @default.
• W2893086056 countsByYear W28930860562021 @default.
• W2893086056 countsByYear W28930860562022 @default.
• W2893086056 crossrefType "journal-article" @default.
• W2893086056 hasAuthorship W2893086056A5021370060 @default.
• W2893086056 hasAuthorship W2893086056A5024232083 @default.
• W2893086056 hasAuthorship W2893086056A5033524900 @default.
• W2893086056 hasAuthorship W2893086056A5038680772 @default.
• W2893086056 hasAuthorship W2893086056A5048445311 @default.
• W2893086056 hasAuthorship W2893086056A5051699142 @default.
• W2893086056 hasAuthorship W2893086056A5054678209 @default.
• W2893086056 hasAuthorship W2893086056A5082791341 @default.
• W2893086056 hasAuthorship W2893086056A5090545099 @default.
• W2893086056 hasBestOaLocation W28930860561 @default.
• W2893086056 hasConcept C121608353 @default.
• W2893086056 hasConcept C126322002 @default.
• W2893086056 hasConcept C141071460 @default.
• W2893086056 hasConcept C143998085 @default.
• W2893086056 hasConcept C197934379 @default.
• W2893086056 hasConcept C2776256026 @default.
• W2893086056 hasConcept C2776694085 @default.
• W2893086056 hasConcept C2777701055 @default.
• W2893086056 hasConcept C2778164965 @default.
• W2893086056 hasConcept C2779013556 @default.
• W2893086056 hasConcept C71924100 @default.
• W2893086056 hasConceptScore W2893086056C121608353 @default.
• W2893086056 hasConceptScore W2893086056C126322002 @default.
• W2893086056 hasConceptScore W2893086056C141071460 @default.
• W2893086056 hasConceptScore W2893086056C143998085 @default.
• W2893086056 hasConceptScore W2893086056C197934379 @default.
• W2893086056 hasConceptScore W2893086056C2776256026 @default.
• W2893086056 hasConceptScore W2893086056C2776694085 @default.
• W2893086056 hasConceptScore W2893086056C2777701055 @default.
• W2893086056 hasConceptScore W2893086056C2778164965 @default.
• W2893086056 hasConceptScore W2893086056C2779013556 @default.
• W2893086056 hasConceptScore W2893086056C71924100 @default.
• W2893086056 hasFunder F4320322120 @default.
• W2893086056 hasIssue "11" @default.
• W2893086056 hasLocation W28930860561 @default.
• W2893086056 hasLocation W28930860562 @default.
• W2893086056 hasLocation W28930860563 @default.
• W2893086056 hasLocation W28930860564 @default.
• W2893086056 hasOpenAccess W2893086056 @default.
• W2893086056 hasPrimaryLocation W28930860561 @default.
• W2893086056 hasRelatedWork W2055244776 @default.
• W2893086056 hasRelatedWork W2348529436 @default.
• W2893086056 hasRelatedWork W2357312190 @default.
• W2893086056 hasRelatedWork W2364112458 @default.

• next